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Abstract Spinal cord injury results in progressive waves of
secondary injuries, cascades of noxious pathological mech-
anisms that substantially exacerbate the primary injury and
the resultant permanent functional deficits. Secondary
injuries are associated with inflammation, excessive cyto-
kine release, and cell apoptosis. The purine nucleoside
guanosine has significant trophic effects and is neuro-
protective, antiapoptotic in vitro, and stimulates nerve
regeneration. Therefore, we determined whether systemic
administration of guanosine could protect rats from some of
the secondary effects of spinal cord injury, thereby reducing
neurological deficits. Systemic administration of guanosine
(8 mg/kg per day, i.p.) for 14 consecutive days, starting 4 h
after moderate spinal cord injury in rats, significantly
improved not only motor and sensory functions, but also
recovery of bladder function. These improvements were
associated with reduction in the inflammatory response to
injury, reduction of apoptotic cell death, increased sparing
of axons, and preservation of myelin. Our data indicate that
the therapeutic action of guanosine probably results from
reducing inflammation resulting in the protection of axons,
oligodendrocytes, and neurons and from inhibiting apopto-
tic cell death. These data raise the intriguing possibility that
guanosine may also be able to reduce secondary patholog-
ical events and thus improve functional outcome after
traumatic spinal cord injury in humans.
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Introduction
Spinal cord injury (SCI) occurs in an instant, but its
devastating effects last a lifetime at huge personal and
economic cost [1]. The spinal cord conveys both afferent
sensory and efferent motor information, so disruption of
spinal cord function results not only in motor paralysis but
also sensory and autonomic impairment distal to the injury
[2, 3]. Sensory dysfunction contributes to the generation of
pressure sores that, like bladder impairment, are a major
source of morbidity and even mortality in those with spinal
cord injury [4].
Restoration of function in longstanding spinal cord
injuries is poor, although some limited functional restora-
tion has been reported [5]. Therefore, there is much interest
in reducing the extent of the initial damage from traumatic
spinal cord injury in the acute phase. Trauma often results
in primary damage resulting from mechanical disruption of
the nerve axons in the spinal cord that is not amenable to
neuroprotective therapy. However, secondary pathological
changes involving cascades of biochemical, molecular, and
cellular changes can produce even more extensive damage,
and these changes are potentially susceptible to therapeutic
intervention with neuroprotective agents [3, 6]. Thus,
pathological changes occur from the moment of injury
and continue for years afterwards and have been divided
into three phases: an acute phase, a phase of secondary
tissue loss, and a chronic phase [3, 6].
In the acute phase, which starts at the moment of injury
and extends over the first few days, numerous pathological
processes begin. Mechanical injury induces an immediate
change in neuronal tracts at the moment of impact, blood
flow is reduced, creating substantial ischemic necrosis [7,
8] and a cascade of pathophysiological processes rapidly
follows mechanical trauma to the spinal cord, resulting in
secondary neuronal damage that can significantly exacer-
bate the original injury [9]. Traumatic injury to the spinal
cord also leads to a strong inflammatory response, with the
recruitment of peripherally derived inflammatory cells,
including macrophages [10]. Damage to the spinal cord
also results in extensive cell proliferation in and around the
epicenter, many of which are microglia and macrophages.
This acute inflammatory response at the site of the initial
lesion is at least partly responsible for secondary spinal
cord pathology [11–13]. The inflammatory cells (particu-
larly macrophages/microglia) can mediate tissue damage by
producing a variety of cytotoxic factors including interleu-
kins [14], tumor necrosis factor-alpha (TNF-alpha) [15],
and reactive nitrogen species [13, 16–18]. Neuronal and
oligodendroglial cell loss is apparent in the lesion epicenter,
and rostral and caudal to it within 4 h of injury [19]. From
days to years after the initial trauma, apoptotic cell death
continues, and scarring and demyelination accompany
Wallerian degeneration. All these processes contribute to
motor and sensory functional deficits [20, 21].
Many pharmacological agents have been reported to
reduce secondary injury and to be neuroprotective in a
variety of animal models; these include anti-inflammatory
[22–24] and antiapoptotic agents [24, 25] and agents that
elevate cyclic adenosine monophosphate (cAMP) [26, 27].
None has yet proved effective in ameliorating the effects of
acute spinal cord injury in clinical trials in humans.
There is increasing evidence that the non-adenine-based
purine guanosine acts as an intercellular signaling molecule. It
is released from cells and has several diverse effects on cells in
vivo and in vitro, particularly trophic effects modulating
cellular growth, differentiation, and survival [28, 29].
Guanosine has a number of effects on various cell types
that make it a good candidate to test as a neuroprotective
agent in acute spinal cord injury since it might potentially
interact with several steps of the biochemical and cellular
cascade. It is neuroprotective [28–32] and stimulates nerve
regeneration [5, 33]. It also protects several cell types against
apoptosis induced by a variety of agents such as staurospor-
ine [34] and beta-amyloid [35] and has been reported to
increase intracellular cAMP [36, 37]. Therefore, in the
present study, we assessed whether guanosine might ame-
liorate tissue damage and enhance functional outcome after
acute spinal cord injury.
Materials and methods
Animals
Adult female Wistar rats (280–300 g body weight, Charles
River) were maintained in a temperature-controlled vivarium
on a 12:12-h light-dark cycle with food and tap water freely
available. Rats were handled daily for 2 weeks before surgery.
Spinal cord injury induction and experimental design
Spinal cords were surgically exposed and compressed with
modified coverslip forceps to produce a moderate traumatic
spinal cord injury [5, 38]. Before surgery, rats were given
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buprenorphine (0.03 mg/kg body weight, subcutaneously)
for pain relief. They were then anesthetized with isoflurane
(3–5%): O2 (1 l/min) and a laminectomy was performed at
T11/T12 to expose the spinal cord that was then crushed
with modified coverslip forceps [5, 38–40]. The forceps
were closed slowly (over 2 s) compressing a 5-mm length
of the spinal cord to a thickness of 1.4 mm for 15 s. The
wound was closed by suturing the muscles and fat pad, and
by clipping the skin with stainless steel clips. Postopera-
tively, the rats were kept quiet and warm.
To evaluate the effect of guanosine on acute phase SCI
pathophysiology, we studied two groups of rats (n=24)
with SCI. After surgery and prior to treatment, behavioral
tests were done for each rat. Two of the total 24 animals
were excluded from the study because of incorrect injury
(BBB score at the surgery day before treatment below 4 or
above 7; in our experience, about 91% of rats with this
degree of crush were within the range of 5 to 6 on the BBB
scale at first day after injury [38]). The 22 rats were then
randomly divided into two groups. Starting 4 h after
surgery, rats received either daily intraperitoneal (i.p.)
injections of 8 mg/kg guanosine or the same volume of
saline containing 0.001 N NaOH [5] for 2 weeks. On day 7
after injury one animal in the saline group was euthanized
because of a severe bladder infection.
Motor and sensory functional recovery assessment
All rats were handled daily for 2 weeks preoperatively to
acclimatize them to the handling and behavioral testing.
After spinal cord compression, the locomotor behavior
segmental reflexes and spinothalamic senses of the rats
were assessed immediately prior to treatment (day 0) and
on days 1, 3, 5, 7, 14, 21, and 28 after the injury. Five tests
were used: an open field walking task [5, 41, 42], hind limb
placing response [38, 40], foot orienting response [38, 40,
43], an inclined plane test [38, 44, 45], and a hot plate test
[46]. Behavioral analyses were performed by individuals
who were blinded with respect to treatment groups.
An open field walking testing (OFWT) was used to
assess the locomotor functional recovery of the hind limb.
It was conducted in a child’s circular plastic swimming pool
(1.3 m in diameter [5, 38]). Cagemates (two animals) were
placed in the center of the open field. They were observed
for 5-min periods and scored for general locomotor ability
using the standard BBB scale. The rats were rated on a
scale of 0 to 21, 0 being no function and 21 being normal.
If the animal stopped moving for a minute, it was placed
again in the center of the open field; otherwise it was left
undisturbed for the duration of the 5-min test period.
Reflexes in the hind limbs were assessed with hind limb
placing response (HLPR) and foot orienting response
(FOR). They were each scored on a scale of 0 to 2, 0
indicating no function and 2 indicating full function [38,
40, 43]. Half-scores were assigned if the behavioral
response appeared intermediate. Hind limbs were scored
separately for each measure. To assess HLPR, we grasped
the hind foot between the thumb and forefinger, pulled
backwards, and then released the foot. The placement of the
foot on the table surface was then scored [38, 40]. The FOR
followed Gruner’s [40] protocol modified from the previous
descriptions of this reflex [43]. When a rat is raised and
lowered by the tail, it shows a characteristic behavior of the
hind legs. A normal rat spreads the toes of its hind leg wide
apart and generally holds them apart for several seconds.
After spinal cord injury, this response is sometimes lost
completely, or reduced in magnitude.
The inclined plane test (IPT) measured the ability of the
rats to maintain their position for 5 s on an inclined plane,
covered by a rubber mat containing horizontal ridges
(1 mm deep, spaced 3 mm apart, self-made) [44]. The rats
were observed as the angle of the surface was increased
from 5 to 90° at 5° intervals. The angle at which the rat
could no longer stay in position was the outcome measure.
Hind limb sensory function was tested by ability to
perceive a standard application of a controlled stimulus to
the trunk below the level of the lesion using a standard
testing apparatus hot plate (IITC Life Science Inc.,
Woodland Hills, CA, USA) [46]. The time taken for the
rat to withdraw its hind paws from contact with the hot
plate was noted. A cutoff time was about 20 s after which
the animals were removed to prevent thermal injury [46].
Recovery of lower urinary tract function
Normal lower urinary tract (LUT) function involves both
spinal and supraspinal circuitry that controls urine storage
and release [47]. Incomplete SCI results in an initial loss
and later partial or complete recovery of LUT function
depending on the severity of injury [48, 49].
After SCI the rats were not capable initially of spon-
taneous micturition, and their bladders were manually
expressed twice daily. The volume of expressed urine was
measured each time, and the data were used to estimate the
initiation of LUT function after SCI.
Histological analysis
Tissue processing and immunohistochemical staining
Twenty-eight days after SCI, animals were killed for
histological and immunohistochemical analysis. Rats were
deeply anesthetized with sodium pentobarbital (50–60 mg/kg
b/w, i.p.) and perfused transcardially; first with 100 ml 0.05M
phosphate-buffed saline (PBS) containing 0.1% heparin,
followed by 300–500 ml of 4% paraformaldehyde (PFA).
The T9 to L1 segments of the spinal cords were removed and
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incubated in the same fixative solution overnight at 4°C and
then cryoprotected in PBS solution containing 30%
sucrose. A segment of each cord, extending from 5 mm
rostral to 5 mm caudal to the lesion site was embedded in
medium (Tissue-Tek® O.C.T. compound, Sakura Finetek
USA, Inc., Torrrance, CA, USA). Serial sections were cut at
20-μm intervals on a cryostat and mounted onto slides
(ColorFrost/Plus; Fisher, Pittsburgh, PA, USA) for histo-
chemical staining. Some cords were transverse-sectioned
for immunohistochemical analysis using the antibodies
described in the section below. Longitudinal sections were
cut for Luxol fast blue staining, a lipophilic dye used
commonly to stain myelin [38].
Details of these immunohistochemical procedures have
been described previously [5, 38]. Briefly, the cryostat
sections were thawed, air-dried, and then incubated in
hydrogen peroxide to reduce endogenous peroxidase
activity, before being rinsed in PBS. The sections were
then incubated in 1% sodium borohydride for 15 min. After
thorough washing with PBS, the sections were treated with
PBS/5% normal goat serum with 0.3% Triton X-100 at
room temperature for 30 min. Overnight incubation with
primary antibody was performed in humidified boxes at
4°C. Macrophages and reactive microglia were detected
with a mouse monoclonal antibody against ED-1 (MCA
341R, 1:500; Serotec, Hornby, ON, Canada) and reactive
astrocytes (astrogliosis) were determined with rabbit anti-
glial fibrillary acidic protein (GFAP) polyclonal antibodies
(Zymed® Lab-SA System Kit, dilution was 1:600, Invi-
trogen Canada Inc., Burlington, ON, Canada). The follow-
ing day, sections were rinsed with PBS and incubated with
either rhodamine-conjugated or fluorescein isothiocyanate
(FITC)-conjugated secondary antibodies. Sections were
then rinsed, coverslipped, and examined under a confocal
microscope.
To determine the spared axons and myelin, double
fluorescent immunolabeling was performed, combining
mouse monoclonal antibodies against neurofilament (RT-
97, 1:10; Developmental Hybridoma Bank) and rabbit anti-
myelin basic protein (MBP) polyclonal antibodies (1:50;
Chemicon Int., Temecula, CA, USA). For double immuno-
labeling, sections were developed using a mixture of FITC-
conjugated goat anti-rabbit IgG and rhodamine-conjugated
goat anti-mouse IgG in 1% normal goat serum and 0.25%
Triton X-100; 1:200 (Invitrogen Canada Inc., Burlington,
ON, Canada) for 2 h. Sections were then rinsed, cover-
slipped, and examined under a confocal microscope. An
investigator who was blinded to the treatment groups
conducted histological analysis.
Terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-biotin nick end labeling assays and quantification For
detection of apoptotic cells, a terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) stain was performed using the “In situ Cell
Death Detection Kit-Fluorescein” (Roche Molecular Bio-
chemicals, Chemicon Int., Temecula, CA, USA), according
to the manufacturer’s instructions. After fixation, tissue
sections were incubated in TdT-mediated dUTP-biotin nick
end labeling (TUNEL) reaction mixture containing TdT
buffer with TdT and biotinylated dUTP in TdT buffer,
incubated in a humid atmosphere at 37°C for 90 min, and
then washed with PBS. The sections were incubated at
room temperature (37°C) for 30 min with fluorescence-
conjugated antibody. The results were analyzed using
confocal fluorescence microscopy. TUNEL-positive cells
in the lesion site in the spinal cord were quantified by
counting positively stained cells. Sections (5–7 per animal)
taken from the penumbra of the lesion and spaced about
100 μm apart were analyzed for each animal (n=3–5
animals per group). Apoptotic cell death was determined by
counting the total number of TUNEL-positive nuclei
through entire cross sections. Low power sections were
digitized and manually outlined using an image analysis
system. Any cavities present in the sections were excluded
from analysis. Data are expressed as cells per section [5].
Quantification For cell counting, 5–7 sections from each
animal (n=5 for each group) at the lesion site (every third
section, 100 μm apart) were analyzed. OX-42-positive
microglia and TUNEL-positive nuclei were counted
through the entire cross section. Data are expressed as the
number of immunostained cells per section (mean ± SEM).
Statistical analysis
All data are presented as mean ± SEM. The statistical
significance of behavioral scores was analyzed by Kruskal-
Wallis nonparametric analysis of variance followed by
Mann-Whitney U tests. Histological data were evaluated by
Student’s t-tests.
Results
Guanosine improves neurological function
Over the course of 4 weeks after spinal cord injury, control
rats (which received saline treatment) recovered occasional
weight-supported plantar steps, but no fore-hind limb
coordination, and had a mean BBB locomotor score of
9.3±0.6 (Fig. 1). In contrast, the guanosine-treated rats
recovered to a BBB score of 14±0.5 (Fig. 1); they exhibited
consistent weight supporting with consistent fore-hind limb
coordination. Hind limb locomotor function in guanosine-
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treated animals was significantly better than in rats that
received saline treatment (P<0.01).
Uninjured rats have normal HLPR scores of 2 [38, 40];
they always place an extended hind limb briskly beneath the
body in a proprioceptive placing response. Injured rats place
their hind limb either partially, or unreliably, or not all,
depending on the time since the injury and the treatment. In
the present study, 4 weeks after injury, control rats with
saline injection attained a 1.0±0.1 HLPR score (Fig. 2) that
was characterized by little or no attempt to place the foot, or
leaving the foot extended with its dorsal surface down. In
contrast, rats treated with guanosine reached a score of 1.7±
0.1 (Fig. 2), with the toes of their hind legs spread wide
apart, a finding which is significantly better than rats that
received saline treatment (P<0.01). Uninjured rats have a
normal FOR score of 2. Saline-treated animals had a FOR
score of 1.0±0.1 (Fig. 3). These rats extended their hind legs
laterally with toe spread but turned their feet outward. When
these rats were lowered, they did not orient their feet toward
the surface. In contrast, the guanosine-treated rats recovered
to a score of 1.7±0.1 (Fig. 3), which is significantly different
(P<0.01) from the saline-treated rats.
Uninjured rats maintain their position on the inclined
plane even at an angle of 90°. In the present study, saline-
treated control rats recovered their ability to maintain their
position at 69°±2 by 4 weeks after injury, whereas
guanosine-treated rats were able to maintain their position
to a mean incline of 79°±1 (Fig. 4) by 4 weeks (P<0.05).
Both saline- and guanosine-treated rats were insensitive to
the thermal stimulus using the hot plate test during the first
2 days after injury. There was a gradual recovery of sensory
function thereafter with recovery being accelerated in
guanosine-treated animals compared to controls (P<0.05)
(Fig. 5).
Guanosine accelerated LUT functional recovery
following SCI
In saline-treated rats the volume of manually expressed
urine increased over the first 7 days after SCI and then
Fig. 1 Open field walking test (OFWT) scores from day 0 (the same
day as surgery, prior to treatment) to 28 days after spinal cord injury
for groups of saline- and guanosine-treated animals (means ± SEM).
Animals with normal spinal cord function score 21, whereas a score of
0 represents total paralysis. Hind limb locomotor function in
guanosine-treated animals (n=11) was significantly better than in rats
that received saline treatment (n=10; P<0.01) from day 1 to 28 after
injury
Fig. 2 Hind limb placing response (HLPR) scores from day 0 (the
same day as surgery, prior to treatment) to 28 days after spinal cord
injury for groups of saline- and guanosine-treated animals (means ±
SEM). Animals with normal spinal cord function score 2, whereas a
score of 0 represents total paralysis. Compared with saline-treated
control animals (n=10), guanosine-treated animals (n=11) had a
significantly better improvement of their hind limb placing responses
(P<0.01) from day 1 to 28 after injury
Fig. 3 Foot orienting response (FOR) scores from day 0 (the same
day as surgery, prior to treatment) to 28 days after spinal cord injury
for groups of saline- and guanosine-treated animals (means ± SEM).
Animals with normal spinal cord function score 2, whereas a score of
0 represents total paralysis. Compared with saline-treated control
animals (n=10), guanosine-treated animals (n=11) had a significantly
better improvement of their foot orienting responses (P<0.01) from
day 1 to 28 after injury
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decreased as spontaneous micturition was reestablished. On
the basis of a previous study [48], the increase in volume of
expressed urine during the first week after injury was
interpreted as resulting from increased bladder size in the
absence of spontaneous micturition. The subsequent de-
crease in manually expressed urine indicates the initiation
of spontaneous micturition (Fig. 6). In guanosine-treated
rats there was a significantly lower residual urine volume
compared to the saline-treated animals (Fig. 6; P<0.001).
More importantly, the rats that received guanosine recov-
ered their LUT function completely by 7 days after injury
(Fig. 6).
Guanosine attenuates macrophage and microglia activation,
but not astrogliosis
After SCI, early inflammatory reactions consisting of
neutrophil and macrophage invasion as well as activation
of microglia and astrocytes were reported in earlier studies
[50, 51]. In the present study, the activated macrophages
and microglia were labeled by the ED-1 immunoreaction.
Guanosine treatment decreased the number of the ED-1
immunopositive cells compared with saline treatment
(Fig. 7a, b, e; P<0.01). However, no differences were
found between the saline and guanosine groups in the
number of activated astroglia (astrogliosis) indicated by the
GFAP immunostaining (Fig. 7c, d).
Guanosine attenuates apoptotic cell death in lesion site
of spinal cord
In the present study, apoptotic cell death induced by
traumatic spinal cord injury was determined with TUNEL
staining. TUNEL-positive nuclei were not uniformly
distributed throughout the cross section of the spinal cord
but were more numerous in the vicinity of the injury center.
Quantification of TUNEL-positive nuclei showed that there
were significantly fewer TUNEL-positive nuclei in the
spinal cords of guanosine-treated rats than saline-treated
control animals (Fig. 8; P<0.001).
Fig. 5 Post-lesional sensitivity of hind limbs touched by a hot plate
from day 0 (the same day as surgery, prior to treatment) to 28 days
after spinal cord injury for groups of saline- and guanosine-treated
animals. Values are the means ± SEM of the average time of
withdrawal of left and right hind paws during contact with a hot
plate. Compared with saline-treated control animals (n=10), guano-
sine-treated animals (n=11) had a significantly better improvement of
their sensory function (*P<0.05) from day 2 to 14 after injury
Fig. 4 Inclined plane test (IPT) scores from day 0 (the same day as
surgery, prior to treatment) to 28 days after spinal cord injury for
groups of saline- and guanosine-treated animals (means ± SEM).
Compared with saline-treated control animals (n=10), guanosine-
treated animals (n=11) had a significantly better score in their inclined
plane test (P<0.05) from day 1 to 28 after injury
Fig. 6 Time course of recovery of lower urinary tract function
(spontaneous voiding). Urinary bladders were expressed every 12 h,
and the collected urine volume was measured. Means ± SEM of the
volume for each group. Compared with saline-treated control animals
(n=10), guanosine-treated animals (n=11) had significantly less urine
collected with time after SCI (*P<0.05; **P<0.001). The rats that
received guanosine had empty bladders by day 7 after injury
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Guanosine increases axon and myelin sparing
Axons were labeled with antibodies against RT-97 (a
neuronal cytoskeletal protein; Fig. 9a, b) and myelin was
labeled with antibodies against MBP (a specific marker for
myelin; Fig. 9c, d). The immunohistochemistry showed that
there were more axons (red, Fig. 9b) and myelin (green,
Fig. 9d) as well as myelinated axons (yellow, Fig. 9f) in the
spinal cords from guanosine-treated animals than in the
cords from saline-treated control rats (Fig. 9a, c, e),
indicating that systemic administration of guanosine is
associated with preservation of tissue including neuronal
and glial elements.
Discussion
These data are the first to demonstrate the ability of guanosine
to act as a neuroprotective agent in vivo. These findings have
potential clinical relevance. Previous studies have shown that
after central nervous system injuries, the concentrations of
guanosine are elevated around the injury and in CSF,
sometimes for prolonged periods [32, 52]. Given the various
trophic and antiapoptotic effects of guanosine in vitro [28, 34,
35], it seemed likely that increasing the concentration of
guanosine in the central nervous system after injury in vivo
might also be neuroprotective. We found that within 7 min of
systemic administration, guanosine enters and progressively
accumulates in the central nervous system (unpublished data),
where it is converted to guanine. It remains to be determined
whether guanosine, guanine, or both are the active neuro-
protective agent. However, guanosine is more readily
deliverable than guanine as a potential neuroprotectant.
The model of incomplete spinal cord injury that we have
used is clinically relevant since about 50% of patients with
spinal trauma have incomplete injury [53]. After incomplete
spinal cord injury, both reflex and voluntary motor
functions below the level of the injury are initially lost;
partial recovery occurs over time [41, 54, 55]. The recovery
of functions mediated by supraspinally controlled reflexes
is slow and incomplete since these require the function of
long tracts, many of which are irreversibly damaged by the
injury [56, 57]. Recovery of locomotion and limb place-
ment depends on ascending and descending spinal cord
tracts, including cortico-, rubro-, reticulo-, vestibulo-, and
raphespinal tracts [58]. The functional loss after spinal cord
injury in rats involves interruption of descending seroto-
nergic [59], reticulospinal, and other descending spinal
tracts that facilitate segmental reflexes [40, 60]. The
ascending spinothalamic tracts mediate the perception of
pain and temperature below the level of the lesion. Since all
of these motor and sensory functions were better in
guanosine-treated animals than in control animals, it
appears that guanosine preserved the function of multiple
long tracts. This was associated with increased axonal
survival and myelin preservation.
Normal micturition requires coordinated activation of the
bladder smooth muscle (detrusor) and the striated muscle of
the external urethral sphincter, controlled by spinal and
supraspinal circuitry [47]. Thus after incomplete spinal cord
injury, initially bladder function is lost, but later partially
Fig. 7 Fluorescent immunostaining using antibodies against a marker
(ED-1) for macrophages and activated microglia in cross sections of
cords from saline-treated (a) and guanosine-treated (b) animals at the
lesion site 4 weeks after injury. There were fewer ED-1-immunola-
beled cells in cords of guanosine-treated rats (b, e) compared to the
cords of vehicle-treated rats (a, e; P<0.01). GFAP-immunofluorescent
staining of cross sections of spinal cords from vehicle-treated (c) and
guanosine-treated (d) animals at the lesion site 4 weeks after injury
showed no difference in immunostaining of GFAP between the cords
of guanosine-treated rats (d) and vehicle-treated rats (c). Scale bar=
50 μm for all
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recovers, the extent of recovery depending on the degree of
preservation of white matter (and hence the long tracts) at
the injury site [48, 49]. Our data revealed that in guanosine-
treated rats, residual urine volume was not only much less
than in controls from the first day after the spinal cord
injury, but that by 7 days after spinal cord injury micturition
had returned to normal. Because guanosine began to exert a
neuroprotective effect on both motor and bladder function
soon after it was first administered, its neuroprotective
effect on each may involve similar mechanisms.
The inherent complexity of the biological system
coupled with the many potential trophic actions of
guanosine make it difficult to determine the mechanisms
by which guanosine produces its effects. Nevertheless,
neuroprotective effects were observed by 24 h after spinal
cord injury. As guanosine was administered 4 h post-
injury, it must have affected processes that were important
between 4 and 24 h post-injury. Within this time frame
after traumatic injury of the spinal cord, both inflamma-
tory responses and apoptosis are prominent. Activation
and proliferation of microglia/macrophages play an im-
portant role in the secondary damage following spinal cord
injury. Thus, cells at the center of the injury cascade are
potential targets for neuroprotective treatments of acute
SCI [21, 61]. As guanosine attenuated the activation and
proliferation of microglia/macrophages following SCI, this
may at least in part provide an explanation for its
neuroprotective effect.
Guanosine has antiapoptotic effects in vitro [34, 35] and
this is another potential mechanism through which guano-
sine might exert beneficial effects after spinal cord injury.
Apoptosis after SCI has been described by many inves-
tigators [15, 62–67]. In these reports, early apoptosis of
neural cells, including neurons, is followed by a delayed
wave of predominantly oligodendroglial-programmed cell
death in degenerating white matter tracts [63–67]. Studies
of apoptosis in white matter after injury raise the possibility
that glial apoptosis occurs, at least in part, as a consequence
of axonal degeneration [68, 69]. However, the presence of
activated microglia in contact with apoptotic oligodendro-
cytes after SCI indicates that this interaction may also
activate cell death programs in the oligodendrocyte [70].
Secondary axonal degeneration may then follow [71, 72].
In the present study, guanosine significantly suppressed
apoptosis in the injured spinal cords when it was system-
ically administered daily for 2 weeks beginning 4 h after
injury. It seems reasonable to postulate that decreasing
Fig. 9 Immunostaining with antibodies against RT-97 for labeling
axons (a, b) and against myelin basic protein (MBP) for central
myelin (c, d) at the lesion site demonstrated the spared tissue. Cross
sections from saline-treated (a) and guanosine-treated cords (b)
demonstrate a neurofilament (NF) immunoreactivity surrounding the
lesion site. c, d Cross sections from saline-treated (c) and guanosine-
treated cords reveal myelin at the lesion site. e, f Merger of the two
images demonstrates NF (red) and MBP (green) double fluorescent
immunolabeling. There were more spared axons and more myelin in
the cords around the lesion site from guanosine-treated animals
compared to the saline-treated group. Scale bar=50 μm for all
Fig. 8 TUNEL-positive apoptotic
cells in spinal cord lesions were
quantified by counting the total
number of TUNEL-positive nuclei
through entire cross sections.
Compared with the cords from
saline-treated animals (a, c), gua-
nosine-treated cords had signifi-
cantly fewer TUNEL-positive
cells (b, c; P<0.001). Scale bar=
50 μm for both a and b
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apoptosis may be an important mechanism through which
guanosine improves neurological outcome after SCI.
Although the intracellular pathways through which
guanosine suppresses apoptotic cell death following spinal
cord injury are not known, a number of intracellular
pathways which protect cells against apoptosis have been
identified. These include the phosphatidylinositol 3-kinase
(PI-3-K)/Akt/protein kinase B (PKB) pathway [73, 74] and
the mitogen-activated protein (MAP) kinase pathway [75].
Our previous studies in vitro have shown that the
antiapoptotic effect of guanosine is mediated by the
activation of both PI-3-K/Akt/PKB and MAPK pathways
[34, 35].
Guanosine can also increase intracellular cAMP in
various cell types [36, 37], and increases in cAMP after
spinal cord injury have been shown to increase recovery
[26, 27]. However, it appears unlikely that increases in
intracellular cAMP are responsible for the effects of
guanosine since the principal effect of cAMP in enhancing
recovery from spinal cord injury appears to be due to its
ability to promote axonal regeneration. In contrast, the
neuroprotective effects we observed early after administra-
tion of guanosine are unlikely to be explained on the basis
of outgrowth of damaged axons. A much longer time frame
could be required for this to occur.
A further possible mechanism by which guanosine might
exert its neuroprotective effects is by stimulating cells to
release and increase synthesis of various trophic factors,
such as basic fibroblast growth factor (bFGF), nerve growth
factor (NGF), and neurotrophin-3 (NT-3) [28]. Such trophic
factors can contribute to tissue preservation after trauma
[67]. The ability of guanosine to stimulate production and
release of trophic factors may not only have early effects,
but also may contribute to the reduced number of apoptotic
cells observed 3 weeks after the injury.
This study is important not only because it is the first to
demonstrate the neuroprotective effect of systemically
administered guanosine in acute spinal cord injury, but also
because it indicates some of the potential mechanisms
whereby guanosine may exert its neuroprotective effects in
vivo. This work provides a basis for further exploration of
the purinergic mechanisms underlying the neuroprotective
effects of exogenous guanosine. Furthermore, and of
potential clinical importance, is that guanosine was effec-
tive when it was administered 4 h after the injury—a
realistic time frame in which to initiate treatment after
spinal cord injury in humans.
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